Trial Profile
Second phase I trial DCVax-Brain in patients with glioblastoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2010
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 03 Aug 2010 Follow-up data from pooled phase I and II trials reported in a Northwest Biotherapeutics media release.
- 21 Oct 2009 Further follow-up data reported in a Northwest Biotherapeutics media release.
- 02 Mar 2009 Long term follow-up data for the second half of 2008 reported in a Northwest Biotherapeutics media release.